Literature DB >> 19958031

Noninvasive evaluation of antiangiogenic effect in a mouse tumor model by DCE-MRI with Gd-DTPA cystamine copolymers.

Xueming Wu1, Eun-Kee Jeong, Lyska Emerson, John Hoffman, Dennis L Parker, Zheng-Rong Lu.   

Abstract

The efficacy of polydisulfide-based biodegradable macromolecular Gd(III) complexes, Gd-DTPA cystamine copolymers (GDCC), for assessing tumor microvascular characteristics and monitoring antiangiogenesis therapy was investigated in a mouse model using dynamic contrast-enhanced MRI (DCE-MRI). The mice bearing human colon tumor xenografts were intraperitoneally injected with an antiangiogenesis agent Avastin three times in a week at a dose of 200 mug/mouse. DCE-MRI with GDCC of 40 kDa (GDCC-40) was performed before and at 36 h after the first treatment with Avastin and at the end of treatment (7 days). Gd(DTPA-BMA) was used as a low molecular weight control. The tumor vascular parameters, endothelial transfer coefficient K(trans) and factional plasma volume f(PV), were calculated from the DCE-MRI data with a two-compartment model. The K(trans) and f(PV) in tumor periphery estimated by DCE-MRI with GDCC-40 before and after the antiangiogenesis treatment correlated well to tumor growth before and after the treatment in the tumor model. In contrast, the parameters estimated by Gd(DTPA-BMA) did not show significant correlation to the therapeutic efficacy. This study demonstrates that DCE-MRI with the biodegradable macromolecular MRI contrast agent can provide effective assessment of the antiangiogenic efficacy of Avastin in the animal tumor model based on measured vascular parameters in tumor periphery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19958031      PMCID: PMC2815092          DOI: 10.1021/mp900153f

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  39 in total

Review 1.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor.

Authors:  H P Gerber; J Kowalski; D Sherman; D A Eberhard; N Ferrara
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

3.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.

Authors:  C J Bruns; C C Solorzano; M T Harbison; S Ozawa; R Tsan; D Fan; J Abbruzzese; P Traxler; E Buchdunger; R Radinsky; I J Fidler
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

4.  Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470.

Authors:  Zaver M Bhujwalla; Dmitri Artemov; Kshama Natarajan; Meiyappan Solaiyappan; Peggy Kollars; Paul E G Kristjansen
Journal:  Clin Cancer Res       Date:  2003-01       Impact factor: 12.531

5.  Application of a biodegradable macromolecular contrast agent in dynamic contrast-enhanced MRI for assessing the efficacy of indocyanine green-enhanced photothermal cancer therapy.

Authors:  Yi Feng; Lyska Emerson; Eun-Kee Jeong; Dennis L Parker; Zheng-Rong Lu
Journal:  J Magn Reson Imaging       Date:  2009-08       Impact factor: 4.813

6.  New model for analysis of dynamic contrast-enhanced MRI data distinguishes metastatic from nonmetastatic transplanted rodent prostate tumors.

Authors:  Xiaobing Fan; Milica Medved; Jonathan N River; Marta Zamora; Claire Corot; Philippe Robert; Philippe Bourrinet; Martin Lipton; Rita M Culp; Gregory S Karczmar
Journal:  Magn Reson Med       Date:  2004-03       Impact factor: 4.668

Review 7.  Angiogenesis modulation in cancer research: novel clinical approaches.

Authors:  Massimo Cristofanilli; Chusilp Charnsangavej; Gabriel N Hortobagyi
Journal:  Nat Rev Drug Discov       Date:  2002-06       Impact factor: 84.694

8.  Extracellular biodegradable macromolecular gadolinium(III) complexes for MRI.

Authors:  Zheng-Rong Lu; Dennis L Parker; K Craig Goodrich; Xinghe Wang; John G Dalle; Henry R Buswell
Journal:  Magn Reson Med       Date:  2004-01       Impact factor: 4.668

Review 9.  VEGF and the quest for tumour angiogenesis factors.

Authors:  Napoleone Ferrara
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

Review 10.  Angiogenesis and antiangiogenic therapy of colon cancer liver metastasis.

Authors:  Oliver Stoeltzing; Wenbiao Liu; Niels Reinmuth; Alexander Parikh; Syed A Ahmad; Young D Jung; Fan Fan; Lee M Ellis
Journal:  Ann Surg Oncol       Date:  2003-08       Impact factor: 5.344

View more
  13 in total

Review 1.  Polymeric materials for theranostic applications.

Authors:  Zhe Wang; Gang Niu; Xiaoyuan Chen
Journal:  Pharm Res       Date:  2013-06-14       Impact factor: 4.200

2.  Metal-containing and related polymers for biomedical applications.

Authors:  Yi Yan; Jiuyang Zhang; Lixia Ren; Chuanbing Tang
Journal:  Chem Soc Rev       Date:  2016-02-24       Impact factor: 54.564

3.  Anti-angiogenic Effects of Bumetanide Revealed by DCE-MRI with a Biodegradable Macromolecular Contrast Agent in a Colon Cancer Model.

Authors:  Anthony S Malamas; Erlei Jin; Qi Zhang; John Haaga; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2015-04-04       Impact factor: 4.200

4.  Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights.

Authors:  Louke J Delrue; Veerle Casneuf; Nancy Van Damme; Peter Blanckaert; Marc Peeters; Wim P Ceelen; Philippe C O Duyck
Journal:  MAGMA       Date:  2011-05-13       Impact factor: 2.310

5.  Polydisulfide manganese(II) complexes as non-gadolinium biodegradable macromolecular MRI contrast agents.

Authors:  Zhen Ye; Eun-Kee Jeong; Xueming Wu; Mingqian Tan; Shouyu Yin; Zheng-Rong Lu
Journal:  J Magn Reson Imaging       Date:  2011-10-26       Impact factor: 4.813

6.  Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats.

Authors:  Xueming Wu; Yuda Zong; Zhen Ye; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2010-07       Impact factor: 4.200

7.  Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models.

Authors:  John J Tentler; Erica L Bradshaw-Pierce; Natalie J Serkova; Kendra M Hasebroock; Todd M Pitts; Jennifer R Diamond; Graham C Fletcher; Mark R Bray; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2010-04-20       Impact factor: 12.531

8.  Polydisulfide Based Biodegradable Macromolecular Magnetic Resonance Imaging Contrast Agents.

Authors:  Zheng-Rong Lu; Xueming Wu
Journal:  Isr J Chem       Date:  2010-08       Impact factor: 3.333

9.  A dedicated automated injection system for dynamic contrast-enhanced MRI experiments in mice.

Authors:  Jan Sedlacik; Adrianne Myers; Ralf B Loeffler; Regan F Williams; Andrew M Davidoff; Claudia M Hillenbrand
Journal:  J Magn Reson Imaging       Date:  2012-09-21       Impact factor: 4.813

10.  Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.

Authors:  Anna G Sorace; C Chad Quarles; Jennifer G Whisenant; Ariella B Hanker; J Oliver McIntyre; Violeta M Sanchez; Thomas E Yankeelov
Journal:  Breast Cancer Res Treat       Date:  2016-01-20       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.